ORIGINAL RESEARCH article
Front. Vet. Sci.
Sec. Comparative and Clinical Medicine
Volume 12 - 2025 | doi: 10.3389/fvets.2025.1596084
Immunotherapeutic efficacy of recombinant canine IL-15 as an adjunct to chemotherapy in canine lymphoma
Provisionally accepted
- 1Jangan University, Gyeonggido, Republic of Korea
- 2Biomaterial R&BD Center, VaxCell-Bio, Gwangju, Republic of Korea
- 3Vet&Gene, Seongnam, Republic of Korea
- 4Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This study evaluated the efficacy and safety of a newly developed rcIL-15, as an adjunct to standard chemotherapy in dogs with lymphoma. Sixty-one dogs were enrolled, with 37 completing the 12week study. The test group received rcIL-15 alongside standard chemotherapy, while the control group received standard chemotherapy alone. Key evaluation parameters included tumor response rates, changes in tumor-related biomarkers, quality of life assessments, and safety profiles. The test group showed higher response rates (CR + PR: 77.8% vs 57.9%) and a lower rate of disease progression (PD: 16.7% vs 31.6%) compared to the control group. Tumor markers, including TK-1 (8 weeks, p < 0.0001), LDH (12 weeks, p = 0.005) and β2-microglobulin (8 and 12 weeks, p <0.05), were significantly reduced in the test group while IFN-γ levels remained stable, suggesting enhanced tumor suppression and immune modulation. Quality of life metrics, including happiness, appetite, and activity levels, improved significantly in the test group. Adverse events were mild, predominantly gastrointestinal symptoms, and were effectively managed. These findings suggest that rcIL-15 is a promising and safe adjunct therapy for canine lymphoma, warranting further investigation in larger trials.
Keywords: Tumor biomarkers, Canine lymphoma, recombinant canine interleukin-15, Immunotherapy, Quality of Life
Received: 19 Mar 2025; Accepted: 13 May 2025.
Copyright: © 2025 Kang, Lee, Kim, Koh, Kang and Park. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hee-Myung Park, Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.